How many patients could benefit from custom genetic therapies? Timothy Yu narrows in on an answer

Tim­o­thy Yu sent shock­waves through the ge­net­ic ther­a­py world four years ago af­ter re­veal­ing that he had de­vel­oped — in un­der a year — a treat­ment tai­lored to a young girl’s unique ge­net­ic mu­ta­tion.

That drug, dubbed Mi­lasen in hon­or of the girl Mi­la, raised the bar on how tru­ly per­son­al­ized a med­i­cine could be, and ig­nit­ed ef­forts to de­vel­op the so-called n-of-1 ther­a­pies for more pa­tients. Yet there was one ques­tion that kept nag­ging at Yu: How many oth­ers like Mi­la were out there?

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN